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The ICP0 protein (bICP0) encoded by bovine herpesvirus 1 is the major viral regulatory protein because it
stimulates all viral promoters and, consequently, productive infection. Like other ICP0 analogues encoded by
Alphaherpesvirinae subfamily members, bICP0 contains a zinc RING finger near its amino terminus that is
necessary for activating transcription, regulating subcellular localization, and inhibiting interferon-dependent
transcription. In this study, we discovered that sequences near the C terminus, and the zinc RING finger, are
necessary for inhibiting the human beta interferon (IFN-) promoter. In contrast to herpes simplex virus type
1-encoded ICP0, bICP0 reduces interferon response factor 3 (IRF3), but not IRF7, protein levels in transiently
transfected cells. The zinc RING finger and sequences near the C terminus are necessary for bICP0-induced
degradation of IRF3. A proteasome inhibitor, lactacystin, interfered with bICP0-induced degradation of IRF3,
suggesting that bICP0, directly or indirectly, targets IRF3 for proteasome-dependent degradation. IRF3, but
not IRF7, is not readily detectable in the nuclei of productively infected bovine cells during the late stages of
infection. In the context of productive infection, IRF3 and IRF7 are detected in the nucleus at early times after
infection. At late times after infection, IRF7, but not IRF3, is still detectable in the nuclei of infected cells.
Collectively, these studies suggest that the ability of bICP0 to reduce IRF3 protein levels is important with
respect to disarming the IFN response during productive infection.
Bovine herpesvirus 1 (BHV-1) is a significant bovine patho-
gen because infection leads to conjunctivitis, pneumonia, gen-
ital disorders, abortions, and “shipping fever,” an upper respi-
ratory infection (50). Infection of bovine cells (10) or calves
(53) leads to rapid cell death and an increase in apoptosis. As
with other Alphaherpesvirinae subfamily members, viral gene
expression is temporally regulated in three distinct phases:
immediate-early (IE), early, or late (29).
The BHV-1 ICP0 protein (bICP0) is encoded by IE tran-
scription unit 1 (54) and activates expression of all three classes
of viral promoters (14). During productive infection, bICP0
protein expression is constitutive because the gene has an IE
promoter and an early promoter (Fig. 1A), and both promoters
are activated by bICP0 (21). The ICP0 homologues encoded by
BHV-1 and herpes simplex virus type 1 (HSV-1) contain a
well-conserved C3HC4 zinc RING finger near their respective
N termini. Mutational analysis has demonstrated the impor-
tance of the C3HC4 zinc RING finger domains of bICP0 and
ICP0 (12, 13, 15, 28). ICP0 (16–18, 35, 36) and bICP0 (28, 41)
colocalize with and disrupt the proto-oncogene promyelocytic
leukemia protein-containing nuclear domains. bICP0 associ-
ates with chromatin-remodeling enzymes, histone deacetylase
1 (57) plus p300 (57), and stimulates plaque formation when
BHV-1 DNA is transfected into bovine cells (22, 28). A panel
of bICP0 transposon insertion mutations that span the entire
protein-coding domain was generated (58) (Fig. 1A). These
bICP0 mutant proteins are expressed at similar levels in trans-
fected cells (58). Sequences located between the zinc RING
finger and the acidic domain are necessary for efficient trans-
activation of a simple viral promoter (58). Although mutations
within the acidic domain do not apparently play an important
role in transactivation, the nuclear localization signal (NLS) at
the C terminus is necessary for wild-type (wt) levels of trans-
activation. Collectively, these studies suggest that bICP0 con-
tains multiple functional domains that activate productive
infection in differentiated cell types and reactivation from
latency.
Infection of cultured human cells with HSV-1 leads to pro-
duction and secretion of interferon (IFN). The ICP0, ICP34.5,
and Us11 genes are the known viral genes that inhibit IFN
activation after infection (33, 38–40, 43). The HSV-1 glyco-
protein gD induces IFN- production in mononuclear cells (30),
in part, because HSV-1 activates interferon response factor 3
(IRF3) in certain cell types (44). Mice lacking type I and type
II interferon receptors in combination with having RAG-2
gene deletions die within a few days following BHV-1 infection
(2). In contrast, BHV-1 infection of wt mice does not lead to
clinical symptoms or extensive viral replication, highlighting
the importance that IFN plays in controlling BHV-1 replica-
tion and pathogenesis. To date, the bICP0 gene is the only
BHV-1 gene known to inhibit interferon signaling (25).
In this study, we identified bICP0 sequences that are neces-
sary for inhibiting transactivation of the human IFN- pro-
moter by IRF3 or IRF7. The mechanisms by which bICP0
inhibits IRF3 versus IRF7 transactivation of the IFN- pro-
moter are different because bICP0 reduces steady-state IRF3
protein levels but not IRF7 protein levels. The zinc RING
finger and sequences near the C terminus are necessary for
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inhibiting IFN- promoter activity and reducing IRF3 protein
levels. In contrast, an expression plasmid containing HSV-1
ICP0 had little effect on IRF3 protein levels in transfected
cells. Following infection of bovine cells, the levels of IRF3
protein, but not IRF7, are reduced. These studies suggest that
the ability of bICP0 to repress IRF3 protein levels promotes
productive infection by suppressing IFN signaling.
MATERIALS AND METHODS
Cell culture and viruses. Human epithelial 293 cells and Madin-Darby bovine
kidney (MDBK) cells were grown in monolayer cultures in Earle’s modified
Eagle’s medium supplemented with 5% fetal bovine serum, penicillin (10 U/ml),
and streptomycin (100 g/ml) in a humidified 5% CO2 atmosphere at 37°C.
Bovine testicle cells (9.1.3 cells) were grown in the same medium with 10% fetal
bovine serum.
The BHV-1 wt Cooper virus strain was propagated and titrated in MDBK
cells. For viral infections, cells were plated onto 100-mm2 culture dishes 24 h
prior to virus infection to obtain 90% confluence at the time of infection. Cells
were infected at a multiplicity of infection (MOI) of 1. After 1 h of adsorption at
37°C, cells were rinsed with phosphate-buffered saline (PBS) and overlaid with
Earle’s modified Eagle’s medium containing 5% or 10% fetal bovine serum.
Expression plasmids. The IFN- chloramphenicol acetyltransferase (CAT)
plasmid was obtained from Stavros Lomvardas (Columbia University, NY). This
construct contains a minimal human IFN- promoter (positions 110 to 20)
upstream of the bacterial CAT gene. The plasmid pCMV2C-bICP0 expresses
Flag-tagged wt bICP0 under the control of the human cytomegalovirus (CMV)
promoter. Generation of bICP0 transposon mutants was described previously
(58). The zinc RING finger mutant 13G/51A contains point mutations within two
conserved amino acids of the C3HC4 zinc RING finger. bICP0 C-terminus
deletion mutants (bICP0 and NcoI) were generated by deleting the SalI-XhoI
fragment (amino acids [aa] 356 to 676) and NcoI-XhoI fragment (aa 607 to 676),
respectively, from the Flag-tagged bICP0 construct (58). A plasmid expressing
HSV-1 ICP0 was obtained from Saul Silverstein (Columbia University, NY).
ICP0-coding sequences were cloned in frame with the Flag epitope in pCMV2C,
and this plasmid is designated Flag-ICP0.
IRF3 and IRF7 expression constructs were obtained from Luwen Zhang
(University of Nebraska, Lincoln, NE).
CAT assays. The IFN- CAT reporter plasmid (2 g) was cotransfected with
bICP0 (1 g) wild-type or transposon plasmids into 293 cells by using TransIT
transfection reagents (Mirus) as described by the manufacturer. Cells were
incubated with the transfection mix for 5 h and then replaced with fresh medium.
After 40 h, cells were lysed by three freeze-thaw cycles in 250 mM Tris-HCl (pH
8.0). CAT assays was performed with 0.2 Ci (7.4 kBq) [14C]chloramphenicol
(Amersham Biosciences, catalog no. CFA754) and 0.5 mM acetyl coenzyme A
(Sigma, catalog no. A2181). Chloramphenicol and its acetylated forms were
separated by thin-layer chromatography and CAT activity measured with a
PhosphorImager (Molecular Dynamics, CA). CAT activity is expressed as fold
induction relative to the vector control. Transfection experiments for CAT assays
were repeated at least three times to confirm the results.
Western blot analysis. 293 or 9.1.3 cells were cotransfected with plasmids
expressing IRF3 or IRF7 and the designated bICP0 plasmids. At 40 h after
transfection, cells were washed with phosphate-buffered saline and suspended in
FIG. 1. Schematic of bICP0 mutants used to localize the domains necessary for inhibiting IFN-dependent transcription. (A) Construction and
identification of the transposon insertion mutants were previously described (50). The transposon insertion sites were first mapped by restriction
endonuclease digestion, and then precise insertion sites were identified by DNA sequencing. The mutants were designated A to O, and the
numbers in parentheses denote the amino acid number that was disrupted by transposon insertion. The positions of the zinc RING finger, acidic
domain, consensus NLS (KRRR), ATG, and bICP0 stop codon are shown. The transposon mutants that had an effect on activating the thymidine
kinase promoter are underlined. (B) Schematic of the 13G/51A and bICP0 deletion mutants. Two amino acid substitutions were inserted into
conserved C’s of the zinc RING finger of bICP0. The bICP0 mutant construct was prepared by digestion of the wt construct with SalI and XhoI,
which deleted sequences from amino acids 357 to 676. The details of the 13G/51A and bICP0 mutants were described previously . The NcoI
mutant was previously described (50). Except for mutants B and L, the remainder of transposon mutants and deletion mutants express similar levels
of bICP0 protein (25, 50).
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lysis buffer (100 mM Tris [pH 8.0], 1 mM EDTA, 100 mM NaCl, 1% NP-40, 1
mM phenylmethylsulfonyl fluoride, and one tablet of complete protease inhibitor
[Roche Molecular Biochemicals] per 10 ml). Cell lysate was incubated on ice for
10 min and then at 4°C with rotation for 10 min and then was clarified by
centrifugation at 10,000  g at 4°C for 15 min. Protein concentrations were
quantified by the Bradford assay. For sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, proteins were mixed with an equal amount of 1 sample loading
buffer (62.5 mM Tris-HCl [pH 6.8], 2% sodium dodecyl sulfate, 50 mM dithio-
threitol, 0.1% bromophenol blue, 10% glycerol) and boiled for 5 min. Proteins
were separated in a 10% bis-cross-linked polyacrylamide gel. After electrophore-
sis, proteins were transferred onto a polyvinylidene difluoride membrane (Im-
mobilon-P; Millipore). Membranes were blocked in Tris-buffered saline that
contained 5% milk. Primary antibodies to IRF3 (C-20 and SC-15991; 1:500
dilution) or IRF7 (Y-19 and SC-15993; 1:500 dilution) were purchased from
Santa Cruz Biotechnology. Membranes were then incubated overnight with the
indicated primary antibody in 5% milk-containing 0.1% Tween 20–Tris-buffered
saline. After washing with 0.1% Tween 20–Tris-buffered saline, membranes were
incubated with donkey anti-goat immunoglobulin G (IgG)-horseradish peroxi-
dase (SC-2020; Santa Cruz Biotechnology) secondary antibody. Immunodetec-
tion was performed with enhanced chemiluminescence Western blotting de-
tection reagents (Perkin-Elmer, MA) in accordance with the manufacturer’s
protocol.
Immunofluorescence. For transfection studies, 9.1.3 cells were plated in four-
well Lab-Tek culture slides (Nunc Life Science Products, catalog no. 154526) at
16 h before transfection. The designated plasmids were cotransfected by using
Lipofectamine 2000 (Invitrogen, catalog no. 116668-019) according to the man-
ufacturer’s protocol. For infection studies, MDBK or 9.1.3 cells were split into
four-well Lab-Tek slides, infected with BHV-1 at an MOI of 1, and then pro-
cessed at different time intervals. At 24 h after transfection or the indicated
infection times, cells were fixed in 4% formaldehyde for 10 min, followed by
three washes with phosphate-buffered saline. Cells were permeabilized by incu-
bating with 100% ethanol (20°C) for 2 min. Slides were then washed three
times and blocked in 4% donkey serum (Sigma, catalog no. D9663) in PBS for
1 h. The designated primary antibodies were used at a 1:50 dilution in PBS and
incubated for 2 h. After three washes with 0.05% Tween 20 in PBS, slides were
incubated with the secondary antibody for 1 h in the dark. Secondary antibodies
used were as follows: Cy2-conjugated donkey anti-goat (catalog no. 705-226-
147), Cy5-conjugated donkey anti-goat (catalog no. 705-176-147), Cy2-conju-
gated donkey anti-rabbit (catalog no. 711-225-152), and Cy5-conjugated donkey
anti-mouse (catalog no. 715-176-150) (Jackson ImmunoResearch Laboratories
Inc.). After slides were washed with 0.05% Tween 20 in PBS, coverslips were
mounted on slides using Gelmount aqueous mounting medium (Sigma, catalog
no. G0918). To visualize the nucleus, DAPI (4,6-diamidino-2-phenylindole)
staining was performed. Images were obtained with a Bio-Rad confocal laser-
scanning microscope (MRC-1024ES) with excitation/emission at 488/520 nm.
RNA extraction and RT-PCR. Total RNA was extracted from 293 cells co-
transfected with IRF3, bICP0, or transposon mutant O by using TRIzol reagent
(Invitrogen, catalog no. 15596-018) as described by the manufacturer. Samples
were digested with DNase I and subjected to reverse transcription-PCR (RT-
PCR). RNA was reverse transcribed using oligo(dT) primers. A mock reaction
was carried out with no reverse transcriptase added. Ten percent of the resulting
cDNA was used as a template for PCR using specific primers for human IRF3
and -actin. PCR products were analyzed on a 1% agarose gel. The following
primer sequences were used: for IRF3, forward primer 5TGGGAGTTCGAG
GTGAC3 and reverse primer 5GGGCTCAGCTCTCCCCAG3; for -actin,
forward primer 5GTGGGG CGCCCCAGGCACCA3 and reverse primer 5C
TCCTTAATGTCACGCACGATTTC3.
RESULTS
Identification of bICP0 domains necessary for inhibiting
IFN- promoter activity. A previous study demonstrated that
bICP0 repressed IFN- promoter activity and interferon-stim-
ulated response element-dependent transcription (25). Fur-
thermore, the zinc RING finger is necessary for inhibiting
IFN-dependent transcription in bovine cells (25). To test
whether other functional domains within bICP0 are necessary
for inhibiting IFN- promoter activity, a series of bICP0 trans-
poson mutants (58) were used (Fig. 1A). These mutants were
previously used to identify functional domains within bICP0
that are necessary for activating a minimal HSV-1 thymidine
kinase promoter (58). The transposon mutants used for this
study express similar levels of bICP0 protein in transfected
cells (58). wt bICP0 or each transposon mutant (mutants A to
O) was cotransfected with either the IRF3 or IRF7 expression
plasmid and the human IFN- CAT construct in human 293
cells. After 40 h of transfection, cell lysate was collected and
CAT assays performed. As expected, IFN- promoter activity
induced by IRF3 or IRF7 was suppressed four- to fivefold in
the presence of wt bICP0 (Fig. 2A and B). In general, the
N-terminus mutants (mutants A, B, D, E, F, G, and H) sup-
pressed IFN- promoter activation with similar efficiency rel-
ative to wt bICP0. Transposon mutants N and O were unable
to suppress IFN- promoter activity induced by IRF7 as effi-
ciently as wt bICP0 or mutant H (Fig. 2A). Transposon mu-
tants I, N, and O also did not inhibit IRF3 induction of the
IFN- promoter (Fig. 2B). Mutant I, however, was not as
efficient as mutant N or O. With respect to mutant N, there was
more variability in the degree of repression compared to mu-
tant O. The deletion mutant NcoI (which lacks aa 607 to 676
at the C terminus and the nuclear localization signal of bICP0
[Fig. 1A]) (58) slightly increased IFN- promoter activity (Fig.
2B). In addition to the zinc RING finger, these results sug-
gested that disruption of bICP0 sequences at site N or O and
deletion of the C terminus (mutant NcoI) eliminated the
ability of bICP0 to suppress IFN- promoter activity.
bICP0 reduces IRF3 protein levels. The ability of bICP0 to
inhibit IRF3- or IRF7-induced IFN- promoter activation sug-
FIG. 2. Identification of bICP0 domains that are necessary to in-
hibit activation of the human IFN- promoter. 293 cells (1  105) were
cotransfected with the IFN- CAT reporter plasmid (1.0 g DNA), 1.0
g of IRF7 (A) or 1.0 g or IRF3 (B) expression plasmid, and the
designated bICP0 expression plasmids (1.0 g DNA). An empty vector
(pcDNA3.1) was used as a control. Cell extracts were collected after
40 h of transfection and analyzed for CAT expression as described in
Material and Methods. The value for the IFN- promoter and IRF3 or
IRF7 in the presence of the blank expression vector was set at 100%.
Data represent the means from at least three experiments. Error bars
show the standard errors for triplicate transfections. *, P 	 0.05.
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gested that bICP0 altered expression or activity of these tran-
scription factors. To begin to understand the molecular basis of
how bICP0 inhibits IFN- promoter activity, we examined
IRF3 or IRF7 protein levels in transfected cells. When 293
cells (Fig. 3 and 4A) or bovine cells (9.1.3) (Fig. 4B) were
cotransfected with plasmids expressing IRF3 and bICP0, IRF3
protein levels were consistently reduced. In contrast, bICP0
did not have a dramatic effect on IRF7 protein levels in the cell
lines examined (Fig. 3A and 4B). RT-PCR was performed to
test whether bICP0 reduced IRF3 mRNA levels. IRF3 mRNA
levels were not reduced dramatically by bICP0 (Fig. 3B), sug-
gesting that bICP0 reduced IRF3 protein levels, not RNA
levels.
The zinc RING finger and C-terminal domains of bICP0 are
important for reducing IRF3 protein levels. Since the zinc
RING finger, mutant O, and the NcoI deletion construct
consistently suppressed IRF3-induced IFN- promoter activity
(Fig. 2), we tested whether these mutants reduced IRF3 pro-
tein levels. For these studies, IRF3 was cotransfected with the
zinc RING finger mutant (13G/51A) or the C-terminal trans-
poson mutant O into 293 or 9.1.3 cells. The 13G/51A mutant or
mutant O did not reduce IRF3 protein levels to the extent that
wt bICP0 did in 293 cells (Fig. 4A) or 9.1.3 cells (Fig. 4B). To
test whether a functional proteasome was necessary for bICP0-
induced IRF3 degradation, cultures were treated with lacta-
cystin, a cell-permeative and irreversible inhibitor of the pro-
teasome (19). Treatment with lactacystin inhibited the ability
of bICP0 to reduce IRF3 protein levels (Fig. 4C).
Immunofluorescent staining of IRF3 and bICP0 was per-
formed to confirm the reduction of IRF3 protein levels in
transfected cells (Fig. 5). bICP0 localizes to promyelocytic leu-
kemia protein-containing nuclear domains (28), and IRF3
shuttles between the cytoplasm and nucleus. In general, the
IRF3 protein is detected primarily in the cytoplasm of unin-
fected cells (55) or cells transfected with an empty vector (Fig.
5, vector panel). As expected, punctate staining of bICP0 was
detected in the nucleus. High levels of IRF3 were detected in
cells cotransfected with IRF3 and pcDNA3.1 (empty vector).
Cells expressing both Flag-tagged bICP0 (red, anti-Flag anti-
body) and IRF3 plasmid contained low levels of IRF3 (green,
anti-IRF3 antibody) (Fig. 5, panel bICP0). 9.1.3 cells express-
ing either Flag-tagged 13G/51A or the Flag-tagged O mutant
contained levels of IRF3 similar to those in cells transfected
with an empty vector. However, many cells cotransfected with
the 13G/51A construct had an altered cytoplasmic IRF3 dis-
tribution. With respect to mutant O, a subset of the total IRF3
FIG. 3. bICP0 expression correlates with reduced IRF3 protein levels. (A) 293 cells (1  105) were transfected with a plasmid expressing IRF3
(2.5 g) or IRF7 (2.5 g) and Flag-tagged bICP0 (2.5 g) expression vector as described for Fig. 2. Whole-cell lysate was collected at 40 h after
transfection and IRF3 or IRF7 protein levels measured by Western blot analysis using 100 g of total cell lysate. (B) 293 cells were transiently
transfected with IRF3 alone, IRF3 and bICP0, or IRF3 and mutant O. Total RNA was isolated 40 h after transfection. For RT-PCR, 1 g of total
RNA was used, and 10% of the resulting cDNA was used as the template for PCR. Primers specific for IRF3 and -actin (control) were used. The
-actin and IRF3 bands were quantified using BioRad Molecular Images. The ratio between IRF3 and -actin was calculated for each lane. The
IRF3 lane was normalized to 1.
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appeared to be present in the nucleus because of the yellowish
appearance of bICP0 spots and reduction of bICP0 fluores-
cence.
To confirm that a functional proteasome was necessary for
bICP0-induced IRF3 degradation, cultures were treated with
lactacystin. Lactacystin treatment yielded numerous bICP0-
positive cells with high levels of IRF3 (Fig. 5, bICP0  lacta-
cystin panel). As expected, when cells were cotransfected with
the empty expression vector plus IRF3 and then treated with
lactacystin (vector  lactacystin panel), many IRF3-expressing
cells were detected. In conclusion, the studies shown in Fig. 3
to 5 demonstrated that wt bICP0 reduced IRF3 protein levels
and that a functional proteasome was necessary for bICP0-
induced IRF3 degradation.
The HSV-1-encoded ICP0 does not reduce IRF3 protein
levels in transiently transfected cells. Although bICP0 and
ICP0 activate productive infection and repress IFN-dependent
transcription, only the C3HC4 zinc RING finger domains of
bICP0 and ICP0 are well conserved (28, 34). To test whether
ICP0, in the absence of other viral genes, reduced IRF3
protein levels, 9.1.3 cells were transfected with a plasmid ex-
pressing Flag-tagged ICP0 and the IRF3 expression plasmid.
Confocal microscopy revealed that all ICP0-positive cells
contained IRF3 (Fig. 6, ICP0IRF3 panels), which was in
stark contrast to the results obtained with bICP0. Although
most ICP0-positive cells contained IRF3 distributed through-
out the cell, there were ICP0-positive cells that had IRF3
localized to the nucleus (Fig. 6, middle panel). As expected,
ICP0 was localized primarily in the nucleus and yielded punc-
tate staining. In cells transfected with an empty expression
vector, IRF3 was consistently localized in the cytoplasm (Fig. 6,
Vector  IRF3 panel). Consistent with the confocal micros-
copy results, Western blot analysis demonstrated that ICP0 did
not have a dramatic effect on IRF3 protein levels (Fig. 6, lower
right panel).
Analysis of IRF3 and IRF7 following infection. In general,
virus infection stimulates transcription of IFN genes and trans-
activation of these genes requires IRF3 activation (30). Phos-
phorylation of IRF3 is necessary for translocation to the nu-
cleus, where it is transcriptionally active (55). To assess the
effect of BHV-1 infection on activation and nuclear transloca-
tion of IRF3 or IRF7, two bovine cell types (9.1.3 and MDBK)
were infected with wt BHV-1 at an MOI of 1 for 4, 16, or 24 h.
Using an MOI of 1, we detected viral proteins in more than
75% of the infected cells at 16 h after infection by confocal
microscopy. After infection, IRF3 or IRF7 localization was
examined by confocal immunofluorescence (Fig. 7). Mock-
infected cultures were used as controls because IRF3 was lo-
calized to the cytoplasm. At 4 h after infection, IRF3 was
located primarily in the nuclei of 9.1.3 cells, indicating that
infection activated IRF3 (Fig. 7). At 16 or 24 h after infection,
IRF3 protein levels appeared to be reduced relative to those at
FIG. 4. bICP0 reduces IRF3 levels in transiently transfected cells. (A) 293 cells were transfected with the designated amounts of plasmids (g
DNA). (B) IRF3 protein expression was analyzed in 9.1.3 cells. IRF3 plasmid (2.5 g) was cotransfected with bICP0 plasmid (2.5 g). At 40 h after
transfection, cell lysate was collected as described in Materials and Methods. (C) 9.1.3 cells were transfected with the designated plasmids (2.5 g
DNA). At 24 h after transfection, the designated cultures were treated with lactacystin (15 M; Calbiochem catalog no. 426100) or dimethyl
sulfoxide, which was used to suspend lactacystin. IRF3 protein levels were detected by Western blot analysis. For each lane, 100 g protein was
used. The level of DNA in each lane was the same because an empty expression vector (pcDNA3.1) was added to the transfection mixture to
make the total DNA equal to 5 g.
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4 h after infection. IRF7, like IRF3, was detected in the nu-
cleus at 4 h after infection (Fig. 7). In contrast to the results
obtained with IRF3, IRF7 was readily detected in the nucleus
at 16 or 24 h after infection. Similar results were obtained with
MDBK cells, and Western blot studies confirmed that IRF3
protein levels were reduced at late times after infection (un-
published data). In summary, these studies suggested that
BHV-1 infection triggered IRF3 and IRF7 activation at early
times after infection, but IRF3 was not detected in the nucleus
at late times after infection.
DISCUSSION
A previous study demonstrated that bICP0 inhibited IFN-
dependent transcription in the absence of other viral genes
(25). In this study, evidence was provided that bICP0 induced
proteasome-dependent degradation of IRF3 but not IRF7.
The zinc RING finger and sequences near the C terminus
(transposon mutant N and O or the NcoI deletion construct)
were necessary for inhibiting IRF7- or IRF3-induced IFN-
promoter activity and IRF3 degradation. Since IFN production
and IFN signaling pathways restrict the host range of BHV-1
(2), identifying viral genes that inhibit IFN signaling and their
mechanism of action is important. Although these studies in-
dicated that bICP0 inhibited IRF3 proteins levels and IFN-
promoter activity, it is likely that other viral genes activate and
then inhibit IFN activity during productive infection, because
HSV-1 encodes several proteins that inhibit the IFN response
to infection.
Following virus infection, two cellular protein kinases, IKK-ε
and TBK-1, phosphorylate serine residues at the C terminus of
IRF3, which induces IRF3 homodimerization and nuclear
translocation (20, 47). Nuclear IRF3 associates with other tran-
scriptional activators, resulting in direct binding and stimula-
tion of IFN- promoter activity (52). IRF3 also directly binds
several consensus DNA binding sites, including the interferon-
FIG. 5. Effect of bICP0 expression on IRF3 protein expression and subcellular localization. Equivalent amounts of IRF3 and Flag-tagged
bICP0 plasmids (wt, 13G/51A mutant, or the mutant O construct) were transfected into 9.1.3 cells. After 24 h of transfection, immunostaining was
performed using the anti-IRF3 and anti-Flag antibodies as described in Materials and Methods. Cultures were then stained with Cy2-conjugated
anti-goat IgG antibody (IRF3, green) and Cy5-conjugated anti-mouse IgG antibody (bICP0, red). Stained cells were visualized by confocal
microscopy. In the cultures containing lactacystin, cultures were transfected and then treated with 15 M lactacystin. The images are representative
of three different experiments (at least 100 cells were examined for each sample in each experiment).
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stimulated response element, and can consequently stimulate
transcription of IFN-stimulated genes in the absence of IFN
(24, 38). HSV-1-encoded ICP0 is an essential component of
the IFN resistance to infection and is sufficient to inhibit in-
duction of IFN-stimulated genes (38–40). Inhibition of IRF3-
and IRF7-mediated activation of IFN-responsive genes re-
quires an intact ICP0 RING finger domain (33). IRF3 and
IRF7 protein levels do not change dramatically following in-
fection of human embryonic lung cells for 10 h with specific
ICP0 mutants or ICP0-expressing virus strains (33). To further
examine the effects of HSV-1 on IRF3 activation, human en-
dometrial adenocarcinoma cells (HEC-1-B) were infected with
Sendai virus to induce IRF3 nuclear accumulation and IFN
production (37). Under these experimental conditions, HSV-
1-encoded ICP0 inhibits IRF3 nuclear accumulation and
IFN- production in HEC-1-B cells. Relative to Sendai virus-
infected cells, IRF3 degradation was enhanced in HEC-1-B
cells following infection with Sendai virus and then with HSV-1
(37). The ability of HSV-1 to induce IRF3 is cell type depen-
dent (44), suggesting that in certain cell types HSV-1 produc-
tive infection can reduce IRF3 protein levels in an ICP0-de-
pendent fashion. The finding that the bICP0 zinc RING finger
domain and sequences near the C terminus, including the NLS,
are important for inhibiting IFN-dependent transcription (25)
is consistent with published findings for HSV-1-encoded ICP0.
In the absence of other viral genes, bICP0 (directly or indi-
rectly) reduced IRF3 protein levels in human or bovine cells.
In contrast to bICP0, HSV-1-encoded ICP0 was unable to
reduce IRF3 protein levels in transiently transfected 9.1.3 cells
as judged by confocal microscopy or Western blot analysis (Fig.
6). The RING finger of HSV-1-encoded ICP0 is an E3 ubiq-
uitin ligase (7, 8, 51). The bICP0 RING finger has also been
reported to possess E3 ubiquitin ligase (11), suggesting that the
bICP0 RING finger is involved with IRF3 degradation. The
FIG. 6. HSV-1-encoded ICP0 does not reduce IRF3 protein levels in transfected cells. IRF3 (0.5 g DNA) and the Flag-tagged ICP0 construct
(0.5 g DNA) were transfected into 9.1.3 cells. As designated, certain cultures were transfected with an empty vector (pCMV2C; 0.5 g DNA)
and the IRF3 expression construct (0.5 g DNA). After 24 h of transfection, immunostaining was performed using the anti-IRF3 and anti-Flag
antibodies. Cultures were then stained with Cy2-conjugated anti-goat IgG antibody (IRF3, green) and Cy5-conjugated anti-mouse IgG antibody
(ICP0, red). Stained cells were visualized by confocal microscopy. The ICP0 panels show just the Flag antibody staining, and the ICP0IRF3
panels show the merge between ICP0 and IRF3 staining. Images are representative of three different experiments (at least 100 cells were examined
for each sample). The lower right panel shows a Western blot study demonstrating that transfection of 9.1.3 cells with increasing concentrations
of HSV-1 ICP0 does not reduce IRF3 protein levels. The amount of Flag-ICP0 construct (g DNA) is shown. For all lanes, 2.5 g IRF3 was used.
As a loading control, -actin levels were examined.
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finding that a functional proteasome was necessary for bICP0-
induced IRF3 degradation supported the contention that the
bICP0 RING finger mediated IRF3 degradation by directly or
indirectly inducing proteasome-dependent IRF3 degradation.
At this time, it is not clear how the C terminus of bICP0
inhibited IRF3-dependent transcription and degradation. Al-
though one could argue that mutations within the C terminus
of bICP0 altered the zinc RING finger conformation, previous
studies indicated that mutant O activated a simple HSV-1
thymidine kinase promoter with an efficiency similar to that of
wt bICP0 (58). Since the zinc RING finger is necessary for
activating transcription, the transposon insertion at O does not
appear to disrupt the zinc RING finger.
As discussed above, IRF3 is a central component of innate
immune responses following virus infection. Thus, it is not
surprising that several viruses, i.e., hepatitis C virus (32), clas-
sical swine fever virus (45), bovine (6) or human (48) respira-
tory syncytial virus, Bunyamwera virus (31), bovine diarrhea
FIG. 7. Localization of IRF3 or IRF7 (green) in BHV-1-infected cells. 9.1.3 cells were infected with BHV-1 at an MOI of 1. Cells were then
immunostained with the anti-IRF3 antibody or anti-IRF7 antibody at 0, 4, 16, or 24 h postinfection (pi). Images were visualized by confocal
microscopy, and the results are representative of three different experiments.
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virus (3), Ebola virus (5), influenza virus (49), human cytomeg-
alovirus (1), human rhinovirus (42), rabies virus (9), and rota-
virus (23), encode proteins that inhibit IRF3. A variety of
mechanisms are utilized to disrupt IRF3 functions, and these
include inhibiting IRF3 phosphorylation, inhibiting transloca-
tion to the nucleus, preventing DNA binding, degrading fac-
tors necessary for activating IRF3, inhibiting IRF3 transcrip-
tion, blocking IRF3 dimerization, or binding and sequestering
IRF3. The NPro protein encoded by bovine diarrhea virus also
induces the proteolytic degradation of IRF3 (26). Further-
more, the nonstructural protein 1 encoded by rotavirus binds
IRF3 (23) and then degrades IRF3 (4). Although bICP0 re-
duced steady-state levels of the IRF3 protein, we have been
unable to coimmunoprecipitate IRF3 and bICP0, suggesting
that these two proteins do not stably interact.
IRF3 activation is considered to be an immediate-early
phase of the IFN response, whereas IRF7 is a component of
the early response (46, 55, 56). Recent studies have suggested
that IRF7 is more important with respect to inhibiting viral
infection when IRF3 versus IRF7 knockout mice are compared
(27). Although it seems clear that IRF7 was activated and
translocated to the nuclei of bovine cells during the early stages
of BHV-1 infection, IRF7 protein levels were not dramatically
reduced relative to IRF3 protein levels. This highlights two
important points: the effect on IRF3 was specific, and bICP0
apparently inhibited IRF7 activity following translocation to
the nucleus. For example, bICP0 may (directly or indirectly)
inhibit IRF7 from binding DNA or associating with cellular
factors necessary for transcriptional activation. It is also pos-
sible that when IRF3 protein levels are very low, IRF7 does not
efficiently activate IFN- promoter activity. Studies designed
to understand the mechanism by which bICP0 interferes with
the ability of IRF7 to activate transcription and how BHV-1
infection induces nuclear translocation of IRF3 and IRF7 will
help us to understand the mechanism by which bICP0 regu-
lates the IFN response following infection.
ACKNOWLEDGMENTS
This work was supported by USDA grants 2005-01554 and 2006-
01627 and, in part, by Public Health Service grant P20RR15635.
We thank Terri Fangman for assistance with confocal microscopy.
REFERENCES
1. Abate, D. A., S. Watanabe, and E. S. Mocarski. 2004. Major human cyto-
megalovirus structural protein pp65 (ppUL83) prevents interferon response
factor 3 activation in the interferon response. J. Virol. 78:10995–11006.
2. Abril, C., M. Engels, A. Limman, M. Hilbe, S. Albini, M. Franchini, M Suter,
and M. Ackerman. 2004. Both viral and host factors contribute to neuro-
virulence of bovine herpesvirus 1 and 5 in interferon receptor-deficient mice.
J. Virol. 78:3644–3653.
3. Baigent, S. J., G. Zhang, M. D. Fray, H. Flick-Smith, S. Goodbourn, and
J. W. McCauley. 2002. Inhibition of beta interfeon transcription by noncyto-
pathogenic bovine viral diarrhea virus is through an interferon regulatory
factor 3-dependent mechanism. J. Virol. 76:8979–8988.
4. Barro, M., and J. T. Patton. 2005. Rotavirus nonstructural protein 1 subverts
innate immune response by inducing degradation of IFN regulatory factor 3.
Proc. Natl. Acad. Sci. USA 102:4114–4119.
5. Basler, C. F., A. Mikulasova, L. Martinez-Sobrido, J. Paragas, E. Muhlberger,
M. Bray, H.-D. Klenk, P. Palese, and A. Garcia-Sastre. 2003. The Ebola virus
VP35 inhibits activation of interferon regulatory factor 3. J. Virol. 77:7945–7956.
6. Bossert, B., S. Marozin, and K.-K. Conzelmann. 2003. Nonstructural pro-
teins NS1 and NS2 of bovine respiratory syncytial virus block activation of
interferon regulatory factor 3. J. Virol. 77:8661–8668.
7. Boutell, C., and R. D. Everett. 2003. The herpes simplex virus type 1 (HSV-1)
regulatory protein ICP0 interacts with an ubiquitinates p53. J. Biol. Chem.
278:36596–36602.
8. Boutell, C., S. Sadis, and R. D. Everett. 2002. Herpes simplex virus type 1
immediate-early protein ICP0 and its isolated RING finger domain act as
ubiquitin E3 ligases in vitro. J. Virol. 76:841–850.
9. Brzozka, K., S. Finke, and K.-K. Conzelmann. 2005. Identification of the
rabies virus alpha/beta interferon antagonist: phospoprotein P interferes
with phosphorylation of interferon regulatory factor 3. J. Virol. 79:7673–
7681.
10. Devireddy, L. R., and C. J. Jones. 1999. Activation of caspases and p53 by
bovine herpesvirus 1 infection results in programmed cell death and efficient
virus release. J. Virol. 73:3778–3788.
11. Dia, L., B. Zhang, J. Fan, X. Gao, S. Sun, K. Yang, D. Xin, N. Jin, Y. Geng,
and C. Wang. 2005. Herpes virus proteins ICP0 and BICP0 can activate
NF-
B by catalyzing I
B ubiquitination. Cell. Signalling 17:217–229.
12. Everett, R. D. 1988. Analysis of the functional domains of herpes simplex
virus type 1 immediate-early polypeptide Vmw110. J. Mol. Biol. 202:87–96.
13. Everett, R. D. 1987. A detailed mutational analysis of Vmw110, a trans-acting
transcriptional activator encoded by herpes simplex virus type 1. EMBO J.
6:2069–2076.
14. Everett, R. D. 2000. ICP0, a regulator of herpes simplex virus during lytic and
latent infection. Bioessays 22:761–770.
15. Everett, R. D., P. Barlow, A. Milner, B. Luisi, A. Orr, G. Hope, and D. Lyon.
1993. A novel arrangement of zinc-binding residues and secondary structure
in the C3HC4 motif of an alpha herpes virus protein family. J. Mol. Biol.
234:1038–1047.
16. Everett, R. D., W. C. Earnshaw, J. Findlay, and P. Lomonte. 1999. Specific
destruction of kinetochore protein CENP-C and disruption of cell division by
herpes simplex virus immediate-early protein Vmw110. EMBO J. 18:1526–
1538.
17. Everett, R. D., P. Lomonte, T. Sternsdorf, R. van Driel, and A. Orr. 1999.
Cell cycle regulation of PML modification and ND10 composition. J. Cell
Sci. 112:4581–4588.
18. Everett, R. D., M. Meredith, A. Orr, A. Cross, M. Kathoria, and J. Parkinson.
1997. A novel ubiquitin-specific protease is dynamically associated with the PML
nuclear domain and binds to a herpesvirus regulatory protein. EMBO J. 16:
1519–1530. (Corrected and republished from EMBO J. 16:566–577.)
19. Fenteany, G. R. F. S., W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber.
1995. Inhibition of proteasome activities and subunit-specific amino-terminal
threonine modification by lactacystin. Science 268:726–731.
20. Fitzgerald, K. A., S. M. McWhirter, K. L. Faja, D. C. Rowe, E. Latz, D. T.
Golenbock, A. J. Coyle, S.-M. Liao, and T. Maniatis. 2003. IKKe and TBKI
are essential components of the IRF3 signaling pathway. Nature 4:491–496.
21. Fraefel, C., J. Zeng, Y. Choffat, M. Engels, M. Schwyzer, and M. Ackermann.
1994. Identification and zinc dependence of the bovine herpesvirus 1 trans-
activator protein BICP0. J. Virol. 68:3154–3162.
22. Geiser, V., and C. Jones. 2003. Stimulation of bovine herpesvirus 1 produc-
tive infection by the adneovirus E1A gene and a cell cycle regulatory gene,
E2F-4. J. Gen. Virol. 84:929–938.
23. Graff, J. W., D. N. Mitzel, C. M. Weisend, M. L. Flenniken, and M. E. Hardy.
2002. Interferon regulatory factor 3 is a cellular partner of rotavirus NSP1.
J. Virol. 76:9545–9550.
24. Guo, J., K. L. Peters, and G. C. Sen. 2000. Induction of the human protein
P56 by interferon, double stranded RNA, or virus infection. Virology 267:
209–219.
25. Henderson, G., Y. Zhang, C. Jones. 2005. The bovine herpesvirus 1 gene
encoding infected cell protein 0 (bICP0) can inhibt interferon-dependent
transcription in the absence of other viral genes. J. Gen. Virol. 86:2697–2702.
26. Hilton, L., K. Moganeradji, G. Zhang, Y.-H. Chen, R. E. Randall, J. W.
McCauley, and S. Goodburn. 2006. The NPro product of bovine viral diar-
rhea virus inhibits DNA binding interfereon regulatory factor-3 and targets
it for proteasomal degradation. J. Virol. 80:11723–11732.
27. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Saton, T. Mizutani, N.
Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7
is the master regulator of type-I interferon-dependent immune responses.
Nature 434:772–777.
28. Inman, M., Y. Zhang, V. Geiser, and C. Jones. 2001. The zinc ring finger in
the bICP0 protein encoded by bovine herpes virus-1 mediates toxicity and
activates productive infection. J. Gen. Virol. 82:483–492.
29. Jones, C. 2003. Herpes simplex virus type 1 and bovine herpesvirus 1 latency.
Clin. Microbiol. Rev. 16:79–95.
30. Katze, M. G., Y. Heng, and M. Gale. 2002. Viruses and interferon: fight for
supremacy. Nat. Rev. Immunol. 2:675–686.
31. Kohl, A., R. F. Clayton, F. Weber, A. Bridgen, R. E. Randall, and R. M.
Elliot. 2003. Bunyamwera virus nonstructural protein NSs counteracts inter-
feron regulatory factor 3-mediated induction of early cell death. J. Virol.
77:7999–8008.
32. Li, K., E. Foy, J. C. Ferreon, M. Nakamura, A. C. M. Ferreon, M. Ikeda, S. C.
Ray, M. Gale, Jr., and S. M. Lemon. 2005. Immune evasion by hepatitis C
virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor
protein TRIF. Proc. Natl. Acad. Sci. USA 102:2992–2997.
33. Lin, R., R. S. Noyce, S. E. Collins, R. D. Everett, and K. L. Mossman. 2004.
The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and
VOL. 81, 2007 BHV-1 ICP0 INDUCES IRF3 DEGRADATION 3085
 at UNIV O
F NEBRASKA-LINCO
LN on Septem






IRF7-mediated activation of interferon-stimulated genes. J. Virol. 78:1675–
1684.
34. Lium, E. K., and S. Silverstein. 1997. Mutational analysis of the herpes
simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for
ICP0 in the expression of the essential 27 gene. J. Virol. 71:8602–8614.
35. Maul, G. G., and R. D. Everett. 1994. The nuclear location of PML, a cellular
member of the C3HC4 zinc-binding domain protein family, is rearranged
during herpes simplex virus infection by the C3HC4 viral protein ICP0.
J. Gen. Virol. 75:1223–1233.
36. Maul, G. G., H. H. Guldner, and J. G. Spivack. 1993. Modification of
discrete nuclear domains induced by herpes simplex virus type 1 immediate
early gene 1 product (ICP0). J. Gen. Virol. 74:2679–2690.
37. Melroe, G. T., N. A. DeLuca, and D. M. Knipe. 2004. Herpes simplex virus
1 has multiple mechanisms for blocking virus-induced interferon production.
J. Virol. 78:8411–8420.
38. Mossman, K. L., P. F. Macgregor, J. J. Rozmus, A. B. Goryachev, A. M.
Edwards, and J. R. Smiley. 2001. Herpes simplex virus triggers and then
disarms a host antiviral response. J. Virol. 75:750–758.
39. Mossman, K. L., H. A. Saffran, and J. R. Smiley. 2000. Herpes simplex virus
ICP0 mutants are hypersensitive to interferon. J. Virol. 74:2052–2056.
40. Mossman, K. L., and J. R. Smiley. 2002. Herpes simplex virus ICP0 and
ICP34.5 counteract distinct interferon-induced barriers to virus replication.
J. Virol. 76:1995–1998.
41. Parkinson, J., and R. D. Everett. 2000. Alphaherpesvirus proteins related to
herpes simplex virus type 1 ICP0 affect cellular structures and proteins.
J. Virol. 74:10006–10017.
42. Peng, T., S. Kotla, R. E. Bumgarner, and K. E. Gustin. 2006. Human
rhinovirus attenuates the type I interferon response by dsrupting activaiton
of interferon regulatory factor 3. J. Virol. 80:5021–5031.
43. Peters, G. A., D. Khoo, I. Mohr, and G. S. Sen. 2002. Inhibition of PACT-
mediated activation of PKR by the herpes simplex simplex virus type 1 Us11
protein. J. Virol. 75:11054–11064.
44. Preston, C. M., A. N. Harman, and M. J. Nicholl. 2001. Activation of
interferon response factor-3 in human cells infected with herpes simplex
virus type 1 or human cytomegalovirus. J. Virol. 75:8909–8916.
45. Rocca, S. A., R. J. Herbert, H. Crooke, T. W. Drew, T. E. Wileman, and P. P.
Powell. 2005. Loss of interferon regulatory factor 3 in cells infected with
classical swine fever virus involves the N-terminal protease, Npro. J. Virol.
79:7239–7247.
46. Sato, M., T. Taniguchi, and N. Tanaka. 2001. The interferon system and
interferon regulatory factor transcription factors—studies from gene knock-
out mice. Cytokine Growth Factor Rev. 12:133–142.
47. Sharma, S., B. R. tenOever, N. Grandvaux, G.-P. Zhou, R. Lin, and J.
Hiscott. 2003. Trigerring the interferon antiviral response through an IKK-
related pathway. Science 300:1148–1151.
48. Spann, K. M., K. C. Tran, and P. L. Collins. 2005. Effects of nonstructural
proteins NS1 and NS2 or human respiratory syncytial virus on interferon
regulatory factor 3, NF-
B, and proinflammatory cytokines. J. Virol. 79:
5353–5362.
49. Talon, J., C. M. Horvath, R. Polley, C. F. asler, T. Muster, P. Palese, and A.
Garcia-Sastre. 2000. Activation of interferon regulatory factor 3 is inhibited
by the influenza A virus NS1 protein. J. Virol. 74:7989–7996.
50. Tikoo, S. K., M. Campos, and L. A. Babiuk. 1995. Bovine herpesvirus 1
(BHV-1): biology, pathogenesis, and control. Adv. Virus Res. 45:191–223.
51. Van Sant, C., R. Hagglund, P. Lopez, and B. Roizman. 2001. The infected
cell protein 0 of herpes simplex virus 1 dynamically interacts with protea-
somes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and
possesses in vitro E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. USA
98:8815–8820.
52. Wathelet, M. G., C. H. Lin, B. S. Parekh, L. V. Ronco, P. M. Howley, and T.
Maniatis. 1998. Virus infection induces the assembly of coordinately acti-
vated transcription factors on the IFN- enhancer in vivo. Mol. Cell 1:507–
518.
53. Winkler, M. T., A. Doster, and C. Jones. 1999. Bovine herpesvirus 1 can
infect CD4 T lymphocytes and induce programmed cell death during acute
infection of cattle. J. Virol. 73:8657–8668.
54. Wirth, U. V., C. Fraefel, B. Vogt, C. Vlcek, V. Paces, and M. Schwyzer. 1992.
Immediate-early RNA 2.9 and early RNA 2.6 of bovine herpesvirus 1 are 3
coterminal and encode a putative zinc finger transactivator protein. J. Virol.
66:2763–2772.
55. Yoneyama, M., W. Suhara, M. Fukuhara, M. Fukuda, E. Nishida, and T.
Fujita. 1998. Direct triggering of the type 1 interferon system by virus
infection: activation of a transcription factors containing IRF-3 and CBP/
p300. EMBO J. 17:1087–1095.
56. Yuang, Y., W. Lowther, M. Kellum, W. C. Au, R. Lin, J. Hiscott, and P. M.
Pitha. 1998. Primary activation of interferon A and interferon B gene tran-
scription by interferon regulatory factor 3. Proc. Natl. Acad. Sci. USA 95:
9837–9842.
57. Zhang, Y., and C. Jones. 2001. The bovine herpesvirus 1 immediate-early
protein (bICP0) associates with histone deacetylase 1 to activate transcrip-
tion. J. Virol. 75:9571–9578.
58. Zhang, Y., and C. Jones. 2005. Identification of functional domains within
the bICP0 protein encoded by BHV-1. J Gen. Virol. 86:879–886.
3086 SAIRA ET AL. J. VIROL.
 at UNIV O
F NEBRASKA-LINCO
LN on Septem
ber 19, 2007 
jvi.asm.org
D
ow
nloaded from
 
